West Pharmaceutical Services, Inc. manufactures and sells containment and delivery systems for injectable drugs and healthcare products in the United States, Germany, France, Other European countries, and internationally. The company operates through two segments, Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers stoppers and seals for injectable packaging systems; syringe and cartridge components, including custom solutions for the needs of injectable drug applications, as well as administration systems that enhance the safe delivery of drugs through advanced reconstitution, mixing, and transfer technologies; and films, coatings, and washing and sterilization processes and services to enhance the quality of packaging components. It also provides drug containment solutions, including CZ, a cyclic olefin polymer in the form of vials, syringes, and cartridges; and self-injection devices, as well as specialized testing services for drug packaging, devices, and administration systems. This segment serves biologic, generic, and pharmaceutical drug companies. The Contract-Manufactured Products segment is involved in the design, manufacture, and automated assembly of components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products. This segment serves pharmaceutical, diagnostic, and medical device companies. The company distributes its products through its sales force and distribution network, as well as contract sales agents and regional distributors. West Pharmaceutical Services, Inc. was founded in 1923 and is headquartered in Exton, Pennsylvania.
Industry, Sector and Symbol
Industry Fabricated rubber products, not elsewhere classified
Sub-IndustryHealth Care Supplies
SectorMedical
SymbolNYSE:WST
CUSIP95530610
Phone610-594-2900
Debt
Debt-to-Equity Ratio0.15
Current Ratio2.82
Quick Ratio2.00
Price-To-Earnings
Trailing P/E Ratio36.33
Forward P/E Ratio35.94
P/E Growth3.27
Sales & Book Value
Annual Sales$1.60 billion
Price / Sales4.65
Cash Flow$4.1406 per share
Price / Cash24.39
Book Value$17.24 per share
Price / Book5.86
Profitability
EPS (Most Recent Fiscal Year)$2.78
Net Income$150.70 million
Net Margins8.20%
Return on Equity14.40%
Return on Assets9.87%
Miscellaneous
Employees7,500
Outstanding Shares73,580,000
West Pharmaceutical Services (NYSE:WST) Frequently Asked Questions
What is West Pharmaceutical Services' stock symbol?
West Pharmaceutical Services trades on the New York Stock Exchange (NYSE) under the ticker symbol "WST."
How often does West Pharmaceutical Services pay dividends? What is the dividend yield for West Pharmaceutical Services?
West Pharmaceutical Services announced a quarterly dividend on Friday, May 4th. Investors of record on Wednesday, July 18th will be given a dividend of $0.14 per share on Wednesday, August 1st. This represents a $0.56 annualized dividend and a yield of 0.55%. The ex-dividend date is Tuesday, July 17th. View West Pharmaceutical Services' Dividend History.
How will West Pharmaceutical Services' stock buyback program work?
West Pharmaceutical Services announced that its Board of Directors has authorized a stock buyback program on Thursday, February 15th 2018, which allows the company to buyback 800,000 shares, according to EventVestor. This buyback authorization allows the company to purchase shares of its stock through open market purchases. Shares buyback programs are generally a sign that the company's board believes its shares are undervalued.
How were West Pharmaceutical Services' earnings last quarter?
West Pharmaceutical Services Inc. (NYSE:WST) announced its quarterly earnings results on Thursday, April, 26th. The medical instruments supplier reported $0.62 earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of $0.64 by $0.02. The medical instruments supplier earned $415.70 million during the quarter, compared to analysts' expectations of $403.87 million. West Pharmaceutical Services had a return on equity of 14.40% and a net margin of 8.20%. West Pharmaceutical Services's revenue was up 7.2% compared to the same quarter last year. During the same period last year, the business earned $0.60 earnings per share. View West Pharmaceutical Services' Earnings History.
When is West Pharmaceutical Services' next earnings date?
What guidance has West Pharmaceutical Services issued on next quarter's earnings?
West Pharmaceutical Services updated its FY18 earnings guidance on Thursday, April, 26th. The company provided EPS guidance of $2.80 to $2.90 for the period, compared to the Thomson Reuters consensus estimate of $2.82. The company issued revenue guidance of $1.72 billion to $1.73 billion, compared to the consensus revenue estimate of $1.72 billion.
What price target have analysts set for WST?
5 analysts have issued 12-month price objectives for West Pharmaceutical Services' stock. Their predictions range from $85.00 to $115.00. On average, they expect West Pharmaceutical Services' share price to reach $104.20 in the next year. View Analyst Ratings for West Pharmaceutical Services.
Who are some of West Pharmaceutical Services' key competitors?
Some companies that are related to West Pharmaceutical Services include McKesson (MCK), Shire (SHP), Align Technology (ALGN), Alexion Pharmaceuticals (ALXN), OTSUKA HOLDINGS/ADR (OTSKY), Amadeus It Group (AMS), Centene (CNC), Fresenius Medical Care AG & Co. KGaA (FME), Essilor International (EI), Teva Pharmaceutical Industries (TEVA), Zimmer Biomet (ZBH), TERUMO Corp/ADR (TRUMY), Eisai (ESALY), AmerisourceBergen (ABC) and SYSMEX Corp/ADR (SSMXY).
Who are West Pharmaceutical Services' key executives?
West Pharmaceutical Services' management team includes the folowing people:
- Mr. Eric M. Green, CEO, Pres & Director (Age 48)
- Mr. William J. Federici, CFO, Sr. VP & Treasurer (Age 58)
- Mr. George Lloyd Miller, Sr. VP, Gen. Counsel & Corp. Sec. (Age 63)
- Ms. Annette F. Favorite, Chief HR Officer and Sr. VP (Age 53)
- Ms. Karen A. Flynn, Chief Commercial Officer and Sr. VP (Age 55)
Has West Pharmaceutical Services been receiving favorable news coverage?
Media headlines about WST stock have been trending somewhat positive this week, Accern Sentiment Analysis reports. Accern identifies positive and negative media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. West Pharmaceutical Services earned a news impact score of 0.18 on Accern's scale. They also gave news articles about the medical instruments supplier an impact score of 45.62 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are West Pharmaceutical Services' major shareholders?
West Pharmaceutical Services' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (8.76%), Franklin Resources Inc. (5.27%), Neuberger Berman Group LLC (4.29%), Select Equity Group L.P. (2.58%), JPMorgan Chase & Co. (2.50%) and Bamco Inc. NY (2.31%). Company insiders that own West Pharmaceutical Services stock include Daniel Malone, Karen Flynn, Patrick J Zenner, Paula A Johnson and William J Federici. View Institutional Ownership Trends for West Pharmaceutical Services.
Which major investors are selling West Pharmaceutical Services stock?
WST stock was sold by a variety of institutional investors in the last quarter, including GW&K Investment Management LLC, Select Equity Group L.P., Lord Abbett & CO. LLC, Neuberger Berman Group LLC, OppenheimerFunds Inc., Carillon Tower Advisers Inc., Eagle Asset Management Inc. and Bamco Inc. NY. Company insiders that have sold West Pharmaceutical Services company stock in the last year include Daniel Malone and William J Federici. View Insider Buying and Selling for West Pharmaceutical Services.
Which major investors are buying West Pharmaceutical Services stock?
WST stock was acquired by a variety of institutional investors in the last quarter, including USS Investment Management Ltd, WCM Investment Management CA, BlackRock Inc., Intermede Investment Partners Ltd, Mawer Investment Management Ltd., Artisan Partners Limited Partnership, Millennium Management LLC and Schroder Investment Management Group. View Insider Buying and Selling for West Pharmaceutical Services.
How do I buy shares of West Pharmaceutical Services?
Shares of WST can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is West Pharmaceutical Services' stock price today?
One share of WST stock can currently be purchased for approximately $100.99.
How big of a company is West Pharmaceutical Services?
West Pharmaceutical Services has a market capitalization of $7.43 billion and generates $1.60 billion in revenue each year. The medical instruments supplier earns $150.70 million in net income (profit) each year or $2.78 on an earnings per share basis. West Pharmaceutical Services employs 7,500 workers across the globe.
How can I contact West Pharmaceutical Services?
West Pharmaceutical Services' mailing address is 530 HERMAN O. WEST DRIVE, EXTON PA, 19341. The medical instruments supplier can be reached via phone at 610-594-2900 or via email at [email protected]
MarketBeat Community Rating for West Pharmaceutical Services (WST)
MarketBeat's community ratings are surveys of what our community members think about West Pharmaceutical Services and other stocks. Vote "Outperform" if you believe WST will outperform the S&P 500 over the long term. Vote "Underperform" if you believe WST will underperform the S&P 500 over the long term. You may vote once every thirty days.
